Abstract

PurposeLow doses of folinic acid (FA) rescue after high-dose methotrexate (HD-MTX) have been associated with increased toxicity, whereas high doses may be related to a decreased antileukemic effect. The optimal dosage and duration of FA rescue remain controversial. This study was designed to investigate, whether a shorter duration of FA rescue in the setting of rapid HD-MTX clearance is associated with increased toxicity.MethodsWe reviewed the files of 44 children receiving a total of 350 HD-MTX courses during treatment for acute lymphoblastic leukemia according to the NOPHO ALL-2000 protocol. Following a 5 g/m2 HD-MTX infusion, pharmacokinetically guided FA rescue commenced at hour 42. As per local guidelines, the patients received only one or two 15 mg/m2 doses of FA in the case of rapid MTX clearance (serum MTX ≤ 0.2 μmol/L at hour 42 or hour 48, respectively). Data on MTX clearance, FA dosing, inpatient time, and toxicities were collected.ResultsRapid MTX clearance was observed in 181 courses (51.7%). There was no difference in the steady-state MTX concentration, nephrotoxicity, hepatotoxicity, neutropenic fever, or neurotoxicity between courses followed by rapid MTX clearance and those without. One or two doses of FA after rapid MTX clearance resulted in a 7.8-h shorter inpatient time than if a minimum of three doses of FA would have been given.ConclusionA pharmacokinetically guided FA rescue of one or two 15 mg/m2 doses of FA following HD-MTX courses with rapid MTX clearance results in a shorter hospitalization without an increase in toxic effects.

Highlights

  • Methotrexate (MTX) is an antimetabolite that functions as a folic acid antagonist

  • We describe a series of 44 patients with pediatric acute lymphoblastic leukemia (ALL) who received a total of 350 courses of 5 g/m2 High-dose methotrexate (HD-MTX) followed by a pharmacokinetically guided folinic acid (FA) rescue, including only one or two 15 mg/m2 doses in the case of rapid MTX clearance, with respect to clinical toxicity and length of hospital stay due to the HD-MTX therapy

  • The patients received a total of 352 HD-MTX courses, but a total of 350 courses were analyzed, as information on two courses of HD-MTX administered at a nonparticipating hospital was missing

Read more

Summary

Introduction

MTX can be administered over a wide dose range, from 20 mg/m2 orally per week in maintenance chemotherapy for acute lymphoblastic leukemia (ALL) to a high intravenous dose of 33,000 mg/m2, when combined with folinic acid (FA) rescue [1]. High-dose methotrexate (HD-MTX) therapy given intravenously, defined as doses of 500 mg/m2 or higher, can cause significant toxicity [2]. Intravenous hydration with urine alkalinization and pharmacokinetically guided FA rescue is used in conjunction with HD-MTX therapy [2]. Increased toxicity after HD-MTX has been attributed to the use of inadequate FA doses and to a delay in commencing FA rescue [6]. The use of higher doses of FA after HD-MTX has been associated with an increased risk of leukemic relapse [8, 9]

Methods
Results
Conclusion
Full Text
Published version (Free)

Talk to us

Join us for a 30 min session where you can share your feedback and ask us any queries you have

Schedule a call